Background There is controversy whether taking β‐blockers or ACE inhibitors (ACEI) is a
risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the …

Background There is an ongoing debate on whether angiotensin‐converting enzyme
inhibitors (ACEI) should be substituted prior to initiation of venom immunotherapy (VIT) for …

Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors, of which the relative importance is unknown. Objective Our aim was to …

Systemic allergic reactions to insect stings affect up to 5% of the population during their
lifetime, and up to 32% of beekeepers. Such reactions can be fatal, albeit very rarely, and …

Background A biomarker that could identify individuals at high risk for severe honeybee
sting allergic reaction and/or systemic adverse events (SAEs) during venom immunotherapy …

BACKGROUND: Case reports have raised concern about concurrent use of angiotensin-
converting enzyme inhibitors (ACE-Is) in patients receiving venom immunotherapy (VIT). No …

Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors. Objective Our aim was to evaluate the association of baseline serum …

Hymenoptera venom allergy ranks among the top three causes of anaphylaxis worldwide,
and approximately one‐quarter of sting‐induced reactions are classified as severe. Fatal …

Whole-body extracts of Hymenoptera were used for diagnosis and treatment until controlled
clinical trials proved them no better than placebo, whereas venom is 85% to 98% effective …

Background Venom immunotherapy (VIT) is commonly used for preventing further allergic
reactions to insect stings in people who have had a sting reaction. The efficacy and safety of …